Five-Year Pompe Therapy Results
BioMarin Reports Five-Year Pompe Therapy Benefits And Promising Duchenne Muscular Dystrophy Data
Anonymous
Key Points
1
At Year 5, ERT-experienced patients had a mean change from PROPEL baseline of 0.7% in percent-predicted six-minute walk distance and -2.8% in percent-predicted forced vital capacity. Among ERT-naïve patients followed through 4.5 years, the respective changes were 10.5% and -4.4%.
2
The PROPEL extension included 62 ERT-experienced patients and 20 ERT-naïve patients; those previously treated had received ERT for a mean of 7.6 years before the study baseline.
3
Treatment-related adverse events occurred in 51.2% of participants; five patients stopped treatment for safety reasons, including two who experienced serious treatment-related adverse events.
4
BioMarin acquired Amicus Therapeutics, which marketed POMBILITI and OPFOLDA, in December—expanding the company’s presence in rare metabolic diseases.
BioMarin reported five-year results from its Phase 3 PROPEL trial showing that POMBILITI plus OPFOLDA helped adults with late-onset Pompe disease maintain walking ability and keep respiratory function relatively stable MarketScreener. The study tracked 82 patients over five years, with no new safety concerns emerging, though some patients stopped treatment due to side effects CNBC.
Different Results for Treatment-Experienced Patients
Patients who had already received enzyme replacement therapy (ERT) showed minimal walking changes after five years. Their six-minute walk distance dropped just 0.7% from the study baseline MarketScreener. By contrast, patients new to ERT treatment gained 10.5% in walking distance over 4.5 years, suggesting the combination therapy offered stronger benefits for treatment-naïve patients RTTNews.
Respiratory Function Remained Relatively Stable
Respiratory function—measured by forced vital capacity—declined modestly in both patient groups. ERT-experienced patients saw a 2.8% decline, while treatment-naïve patients experienced a 4.4% decline over 4.5 years MarketScreener. These relatively small drops suggest the therapy helped preserve lung function, a critical measure in Pompe disease management CNBC.
Safety Profile Manageable but Not Without Concerns
Treatment-related side effects occurred in just over half of patients (51.2%), though most were manageable RTTNews. However, five patients discontinued the therapy due to safety issues, including two who experienced serious adverse events MarketScreener. The longer-term safety data reassured regulators that the combination posed no unexpected risks after five years of use.
BioMarin Expands Rare Disease Portfolio After Amicus Acquisition
BioMarin acquired Amicus Therapeutics in December, gaining control of POMBILITI and OPFOLDA MarketScreener. The acquisition strengthens BioMarin's position in rare metabolic diseases like Pompe disease, which affects fewer than 5,000 people in the U.S. The five-year data validates the long-term value of the drugs for a company now committed to their development and commercialization GuruFocus.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
14
Reach
24
A
AnonymousAuthor
